Sadao Kuromitsu

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Correction: Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies.

Correction: Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies.

Journal: Scientific reports
Published: July 02, 2026

Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies.

Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies.

Journal: Scientific reports
Published: October 12, 2023

Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients.

Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients.

Journal: PloS one
Published: May 09, 2020

A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth.

A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth.

Journal: Biochemical and biophysical research communications
Published: November 08, 2019

Identification of a novel oncogenic mutation of FGFR4 in gastric cancer.

Identification of a novel oncogenic mutation of FGFR4 in gastric cancer.

Journal: Scientific reports
Published: May 24, 2019

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia.

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia.

Journal: Oncotarget
Published: January 02, 2019

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.

Journal: Molecular cancer therapeutics
Published: August 10, 2018

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

Journal: Investigational new drugs
Published: March 08, 2017

ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.

ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.

Journal: Cancer science
Published: August 19, 2016

ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.

ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.

Journal: Molecular cancer therapeutics
Published: April 06, 2016

In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).

In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).

Journal: Investigational new drugs
Published: May 13, 2014

Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.

Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2014
Showing 1-12 of 13

Last Updated: 09/26/2026